SSY Group (SEHK:2005) - Aktienkurs, Nachrichten und Analyse

2005 Aktienübersicht

2005 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	5/6
Künftiges Wachstum	2/6
Vergangene Leistung	5/6
Finanzielle Gesundheit	5/6
Dividenden	3/6

Belohnungen

61.1% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 5.81% pro Jahr

Die Erträge stiegen im vergangenen Jahr um 14.6%

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Dividende von 4.72% ist nicht gut durch freie Cashflows gedeckt

SSY Group Limited Wettbewerber

Luye Pharma Group

SEHK:2186

HK$9.9b

Shandong Xinhua Pharmaceutical

SEHK:719

HK$9.9b

China Traditional Chinese Medicine Holdings

SEHK:570

HK$11.5b

Grand Pharmaceutical Group

SEHK:512

HK$16.0b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für SSY Group
Historische Aktienkurse
Aktueller Aktienkurs	HK$3.81
52-Wochen-Hoch	HK$5.20
52-Wochen-Tief	HK$3.31
Beta	0.62
11 Monat Veränderung	-0.52%
3 Monate Veränderung	8.55%
1 Jahr Veränderung	-23.34%
33 Jahre Veränderung	1.06%
5 Jahre Veränderung	-40.00%
Veränderung seit IPO	893.91%

Aktuelle Nachrichten und Updates

Recent updates

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 31

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Mar 29

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

Mar 28

Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching

Mar 06

Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005)

Feb 13

SSY Group Limited's (HKG:2005) Price In Tune With Earnings

Dec 29

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

Sep 26

SSY Group (HKG:2005) Will Pay A Larger Dividend Than Last Year At HK$0.07

Sep 03

If EPS Growth Is Important To You, SSY Group (HKG:2005) Presents An Opportunity

Aug 31

Estimating The Intrinsic Value Of SSY Group Limited (HKG:2005)

Jun 24

Aktionärsrenditen

	2005	HK Pharmaceuticals	HK Markt
7D	-1.3%	0.8%	0.4%
1Y	-23.3%	-7.5%	12.0%

Rendite im Vergleich zur Industrie: 2005 unter dem Niveau der Branche Hong Kong Pharmaceuticals , die im vergangenen Jahr eine Rendite von -7.5% erzielte.

Rendite vs. Markt: 2005 hinter dem Markt Hong Kong zurück, der im vergangenen Jahr eine Rendite von 12 erzielte.

Preisvolatilität

Is 2005's price volatile compared to industry and market?
2005 volatility
2005 Average Weekly Movement	5.3%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.3%

Stabiler Aktienkurs: 2005 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: 2005Die wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1999	5,800	Jiguang Qu	www.ssygroup.com.hk

Die SSY Group Limited, eine Investment-Holdinggesellschaft, erforscht, entwickelt, produziert, handelt und verkauft verschiedene pharmazeutische Produkte an Krankenhäuser und Händler in der Volksrepublik China und international. Das Unternehmen bietet intravenöse Infusionslösungen an, darunter Weichbeutel ohne PVC, aufrechte Weichbeutel, PP-Kunststoffflaschen und Infusionslösungen in Glasflaschen, sowie Ampulleninjektionen. Darüber hinaus bietet es Injektionen in kleinen Mengen, orale Präparate, Präparate der chinesischen Medizin und biologische Präparate sowie pharmazeutische Massenprodukte und medizinische Materialien an.

SSY Group Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von SSY Group im Vergleich zum Marktanteil des Unternehmens?
2005 grundlegende Statistiken
Marktanteil	HK$11.57b
Gewinn(TTM)	HK$1.37b
Umsatz(TTM)	HK$6.47b

8.3x

Kurs-Gewinn-Verhältnis

1.7x

Kurs-Umsatz-Verhältnis

Ist 2005 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
2005 Gewinn- und Verlustrechnung (TTM)
Einnahmen	HK$6.47b
Kosten der Einnahmen	HK$2.95b
Bruttogewinn	HK$3.52b
Sonstige Ausgaben	HK$2.15b
Umsatz	HK$1.37b

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.46
Bruttomarge	54.39%
Nettogewinnspanne	21.11%
Schulden/Eigenkapital-Verhältnis	47.7%

Wie hat sich 2005 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

4.7%

Aktuelle Dividendenrendite

39%

Ausschüttungsquote

2005 Aktienübersicht

Belohnungen

Risikoanalyse

SSY Group Limited Wettbewerber

SEHK:2186

HK$9.9b

SEHK:719

HK$9.9b

SEHK:570

HK$11.5b

SEHK:512

HK$16.0b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Chairman & CEO recently bought HK$3.4m worth of stock

Price target increased by 14% to HK$6.38

SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg)

SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China

SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China

Investor sentiment improves as stock rises 18%

Recent updates

Chairman & CEO recently bought HK$3.4m worth of stock

Price target increased by 14% to HK$6.38

SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg)

SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China

SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China

Investor sentiment improves as stock rises 18%

Chairman & CEO recently bought HK$4.8m worth of stock

Analysts Just Slashed Their SSY Group Limited (HKG:2005) EPS Numbers

SSY Group Limited Announces Update on Product Development

Chairman & CEO recently bought HK$1.5m worth of stock

Consensus EPS estimates fall by 10%

Price target decreased by 10% to HK$5.58

SSY Group Limited Announces Update on Product Development

First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023)

SSY Group's (HKG:2005) Dividend Will Be HK$0.08

First half dividend increased to HK$0.08

SSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024

SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited's (HKG:2005) P/E Is On The Mark

Investor sentiment deteriorates as stock falls 16%

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China

Upcoming dividend of HK$0.10 per share

SSY Group (HKG:2005) Is Paying Out A Larger Dividend Than Last Year

SSY Group's (HKG:2005) Upcoming Dividend Will Be Larger Than Last Year's

SSY Group Limited Provides Update on Product Development

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Chairman & CEO recently bought HK$2.5m worth of stock

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

SSY Group Limited, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching

SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China

SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market

SSY Group Limited Receives Approval for Gliclazide Tablet

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China

Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005)

SSY Group Limited Announces Update on Product Development

SSY Group Limited Provides Update on Product Development

SSY Group Limited Appoints Liu Wenjun as Non-Executive Director

Ssy Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited's (HKG:2005) Price In Tune With Earnings

SSY Group Limited Provides Update on Product Development

Chairman & CEO recently bought HK$4.7m worth of stock

Erträge & Einnahmen